Keywords: Bristol-Myers, Biocon, IN-105, Oral insulin candidate, Option agreement
Bristol-Myers Squibb signs option for Biocon's oral insulin drug candidate
Article | 19 November 2012
Bangalore, India-based biotechnology firm Biocon (BSE: 532523) has entered into an option agreement with US drug major Bristol-Myers Squibb (NYSE: BMY) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
